Published in Pharma Business Week, May 7th, 2012
Under the new agreement, Amgen and PRA will work together to execute Phase III studies related to Amgen's current biosimilar portfolio. The agreement is intended to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.